ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
March 26 2015 - 8:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that Daniel Soland has joined its Board of Directors. Mr.
Soland is a seasoned pharmaceutical executive with over 30 years of
experience in the biopharmaceutical industry.
“Dan brings a tremendous wealth of commercial experience to the
Board and his perspective and insight will be welcomed as ACADIA
advances NUPLAZID™ towards registration and prepares for the
planned launch of NUPLAZID in the United States,” said Leslie L.
Iversen, Ph.D., Chairman of ACADIA’s Board of Directors. “In
addition to his extensive commercial experience in launching new
drugs and life cycle management, he has led manufacturing and
quality organizations and has been instrumental in driving growth
in the companies he has served.”
Mr. Soland previously served as Senior Vice President and Chief
Operating Officer of ViroPharma starting in 2008 until it was
acquired in 2014, and as Vice President and Chief Commercial
Officer of the Company from 2006 to 2008. During his tenure at
ViroPharma, Mr. Soland managed the commercial, manufacturing and
quality organizations, helped build the company’s commercial
infrastructure in the United States, Europe, and Canada and led the
launch of Cinryze®, one of the most successful ultra-orphan drugs
in the United States. Mr. Soland served as President, Chiron
Vaccines, of Chiron Corporation from 2005 to 2006 and led the
growth of the vaccine business to over $1 billion in sales. From
2002 through 2005, Mr. Soland served as President and Chief
Executive Officer of Epigenesis Pharmaceuticals. Earlier in his
career, Mr. Soland worked for GlaxoSmithKline in increasing roles
of responsibility from 1993 to 2002, including as Vice President
and Director, Worldwide Marketing Operations, GSK Biologicals. He
currently serves on the board of directors of Tarsa Therapeutics
and DBV Technologies SA. Mr. Soland earned his B.S. in Pharmacy
from the University of Iowa.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by
NUPLAZID (pimavanserin), for which we have reported positive Phase
III trial results in Parkinson’s disease psychosis and which has
the potential to be the first drug approved in the United States
for this disorder. Pimavanserin is also in Phase II development for
Alzheimer’s disease psychosis and has successfully completed a
Phase II trial in schizophrenia. ACADIA also has clinical-stage
programs for chronic pain and glaucoma in collaboration with
Allergan, Inc. All product candidates are small molecules that
emanate from internal discoveries. ACADIA maintains a website at
www.acadia-pharm.com to which we regularly post copies of our press
releases as well as additional information and through which
interested parties can subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
registration and planned launch of NUPLAZID (pimavanserin) for the
treatment of Parkinson’s disease psychosis (PDP); the potential for
pimavanserin to be the first drug approved in the United States for
PDP, if approved at all; and the progress, timing and results of
ACADIA’s drug discovery and development programs, either alone or
with a partner, including the progress and expected timing of
clinical trials. These statements are only predictions based on
current information and expectations and involve a number of risks
and uncertainties. Actual events or results may differ materially
from those projected in any of such statements due to various
factors, including the risks and uncertainties related to those
inherent in drug discovery, development, approval, and
commercialization, and collaborations with others, and the fact
that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year
ended December 31, 2014 as well as ACADIA’s subsequent filings
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
ACADIA Pharmaceuticals Inc.Steve Davis, Interim Chief Executive
OfficerLisa Barthelemy, Director of Investor Relations(858)
558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024